Pathogenics, Inc.’s scientific development team are a well-rounded group of respected international academic researchers, leading clinical investigators, and experienced biopharmaceutical advisors and consultants.
Dr. Markus Nagl, MD
Markus Nagl, MD, is a co-inventor of the anti-infective properties of N-Chlorotaurine. He is an Associate Professor for Hygiene and Microbiology at the University of Innsbruck, Institute of Hygiene and Social Medicine, Department of Hygiene located in Innsbruck, Austria. His relevant research interests include the areas of: (1) innate immunity; intracellular killing of pathogens by leukocytes – functions of oxidants in intracellular killing, direct activity of endogenous oxidants (N-chlorotaurine) against pathogens; (2) clinical application of endogenous oxidants – clinical trials of the tolerability and efficacy of N-chlorotaurine in topical treatment of infections, e.g. conjunctivitis, otitis and sinusitis, leg ulcer, cystitis; and, (3) antimicrobial agents (antibiotics, disinfectants . . . ) and interaction of these agents with innate immunity. Dr. Nagl has authored numerous scientific papers on these subjects, and has been the recipient of research grants from the Austrian Science Fund, Austrian National Bank and the Legerlotz-Foundation. He is also the winner of the Austrian Hygiene Prize (1999), and has been a repeat Academic visitor at the Rayne Institute, Centre for Molecular Medicine, University College London.
Dr. Waldemar Gottardi, PhD
Waldemar Gottardi, Ph.D., is the inventor of the crystalline sodium salt form of the endogenous oxidant N-chlorotaurine. His main interests comprise development of new halogen-based active agents and exploration of the chemism of bactericidal processes. He is a retired Associate Professor in Technical Hygiene at the Medical University of Innsbruck, Austria. His relevant research interests include the areas of: (1) chemical disinfection – basic research on microbicidal action of iodine and active chlorine compounds; (2) clinical application of endogenous oxidants – clinical trials on the tolerability and efficacy of N-chlorotaurine in topical treatment of infections; and, (3) anitimicrobial agents – in vitro and in-vivo activity of disinfectants, interactions of these agents with innate immunity. Dr. Gottardi has authored numerous scientific papers on these subjects, and has been the recipient of research grants from the Austrian Science Fund, Austrian National Bank and the Legerlotz-Foundation.
Dr. Barry A. Schlech, PhD
Barry A. Schlech, Ph.D., is a pharmaceutical microbiologist and retired as Vice President of R&D Pharmaceutical Microbiology, Alcon Laboratories, Inc. based in Fort Worth, Texas, where he was responsible for directing Alcon’s research and development of anti-infective agents like the synthetic aganocides — including N-Chlorotaurine (NCT) — as antimicrobials for ophthalmic indications. His specialties include antimicrobial agents, ophthalmic infections, sterilization, and pharmaceutical microbiology. As Alcon’s chief R&D microbiologist, Dr. Schlech directed the the anti-infective research programs and authored hundreds of new drug applications (INDs, IDEs, NDAs, and PMAs) by the R&D departments of microbiology, package and process development, technical documentation, pharmaceutics/formulations, and analytical chemistry. Dr. Schlech is a graduate of the University of Texas at Austin where he received his B.A. degree in zoology, and M.A. and Ph.D. degrees in microbiology. In 1989, Dr. Schlech completed the Program for Management Development at the Harvard Business School.
Dr. Gaurav Chandra, MD/MBA
Gaurav Chandra, MD/MBA, obtained his medical degree from Kasturba Medical College, Manipal, India and conducted his surgery residency at Montefiore Albert Einstein College of Medicine, Bronx, New York. He holds a Masters Degree in Business Administration from the Univ. of Colorado-Denver. He has served as a Senior Research Assistant/Clinical Fellow Clinical Islet Cell Transplantation and Cell Biology at Joslin Diabetes Center (Mass General Hospital/Brigham Woman’s Hospital) working on Human Islet Transplantation as part of an initiative to develop cures for Diabetes. He is presently a Consultant Surgeon in the Department of Burn Surgery, Red Cross Children’s Hospital Cape Town, South Africa. In addition to now serving as the COO and Vice President of BioClonetics (2015-present), he is also the CEO of GlobeMD (2014-present). Through partnering with global hospitals and healthcare providers, GlobeMD is the first ever comprehensive digital marketplace for medical tourists. Dr. Chandra is also the CEO and Chairman of United International Diagnostics and United International Health Solutions (Hospitals) (2014-2016). As CEO of United International Diagnostics, he guided the launch and successful establishment of a multi-million dollar Diagnostic Center Network in India that provides a complete Diagnostic Solution to Hospitals and Medical Institutions, leading a company of 100+ employees to success. Dr. Chandra has also served in the past 3 years as CEO of Chemokind Inc. (2015-2016), a company that incorporates therapeutic strategies inspired by biological design. In the past 3 years, Dr. Chandra has also served as CEO of Advanced Medical Information Technology (2013-2014), a company providing mobile health platforms that simplifies healthcare management for patients and physicians.